Copenhagen, January 31st, 2023 – MC2 Therapeutics A/S, a commercial stage pharmaceutical company, engaged in research in skin biology and development of novel treatment paradigms for autoimmune and chronic inflammatory skin conditions, announces Chief Executive Officer Jesper J. Lange, will give a business update in person at the BIO CEO & Investor Conference being held February 6th – 7th, 2023 at the Marriott Marquis in New York City.
The presentation takes place 4pm ET on Tuesday, February 7th, 2023 in the Palace Room at the Marriott Marquis.
MC2 Therapeutics recently announced breakthrough discovery of novel biological treatment paradigm applicable for a number of urea associated skin diseases affecting millions of people globally, incl. Chronic Kidney Disease associated Pruritus (Ph2 ongoing) and Vulva Lichen Sclerosus (Ph2 starting H1 2023).
MC2 Therapeutics has discovered that carbamylation of proteins, peptides and amino acids in the skin, caused by isocyanate, may be the root cause of several poorly understood skin diseases such as CKD-aP and Vulva Lichen Sclerosus.
About MC2 Therapeutics A/S
MC2 Therapeutics A/S is a privately held commercial stage pharmaceutical company committed to research of skin biology and development of novel treatment paradigms for people with autoimmune and chronic inflammatory skin conditions.
Its innovative approach to address complex challenges more effectively is anchored in deep understanding of the skin biology combined with learnings from the pathophysiology across disease segments. Fueled by an entrepreneurial mindset and creativity, MC2 Therapeutics aims to set new standards in treatment satisfaction for people with skin conditions.
For additional information on MC2 Therapeutics Group, please visit www.mc2therapeutics.com
MC2 Therapeutics A/S
Investors: Lonni Goltermann, +45 2018 1111 or log@mc2therapeutics.com
BACK
